(Q30675209)

26 June 2017

title

A new structural class of selective and non-covalent inhibitors of the chymotrypsin-like activity of the 20S proteasome (English)

1 reference

26 June 2017

García-Echeverría C

1

1 reference

26 June 2017

Imbach P

2

1 reference

26 June 2017

France D

3

1 reference

26 June 2017

Fürst P

4

1 reference

26 June 2017

Lang M

5

1 reference

26 June 2017

Noorani AM

6

1 reference

26 June 2017

Scholz D

7

1 reference

26 June 2017

Zimmermann J

8

1 reference

26 June 2017

Furet P

9

1 reference

26 June 2017

language of work or name

English

0 references

publication date

1 May 2001

1 reference

Bioorganic & Medicinal Chemistry Letters

26 June 2017

published in

1 reference

26 June 2017

volume

11

1 reference

26 June 2017

issue

10

1 reference

26 June 2017

page(s)

1317-1319

1 reference

Proteasomes: structure and biology

26 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900205-0

7 January 2021

Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900205-0

7 January 2021

The MHC class I ligand-generating system: roles of immunoproteasomes and the interferon-gamma-inducible proteasome activator PA28.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900205-0

7 January 2021

How proteolysis drives the cell cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900205-0

7 January 2021

The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900205-0

7 January 2021

Proteasome inhibitors: from in vitro uses to clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900205-0

7 January 2021

Proteasome inhibition: a new strategy in cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900205-0

7 January 2021

Proteasome inhibitors as anti-cancer agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900205-0

7 January 2021

Proteasome inhibitors as potential novel anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900205-0

7 January 2021

Selective proteasome inhibitors as anti-inflammatory agents

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900205-0

7 January 2021

Proteasome inhibitors: valuable new tools for cell biologists

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900205-0

7 January 2021

Inhibitors of human immunodeficiency virus type 1 protease containing 2-aminobenzyl-substituted 4-amino-3-hydroxy-5-phenylpentanoic acid: synthesis, activity, and oral bioavailability

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900205-0

7 January 2021

Inhibitors of HIV-1 proteinase containing 2-heterosubstituted 4-amino-3-hydroxy-5-phenylpentanoic acid: synthesis, enzyme inhibition, and antiviral activity

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900205-0

7 January 2021

An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900205-0

7 January 2021

Modeling of the binding mode of a non-covalent inhibitor of the 20S proteasome. Application to structure-based analogue design

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900205-0

7 January 2021

10.1016/S0960-894X(01)00205-0

Identifiers

DOI

1 reference

26 June 2017

1 reference